Korsana Biosciences, Inc.
KRSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001755237
No open-market purchases or sales by Korsana Biosciences, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $16.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Korsana Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Korsana Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pernice Michelle Patricia | Director | – | Sep 10, 2026 | 1 |
| Shah Nimish P | Director | – | Sep 10, 2026 | 1 |
| Harwin Peter Evan | Director, 10% Owner | – | Sep 10, 2026 | 1 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Owner | – | Sep 10, 2026 | 1 |
| Fairmount Funds Management LLC | Director, 10% Owner | – | Sep 10, 2026 | 1 |
| Kiselak Tomas | Director, 10% Owner | – | Sep 10, 2026 | 1 |
| Fairmount Healthcare Co-Invest VI L.P. | Director, 10% Owner | – | Sep 10, 2026 | 1 |
| Gottesdiener Andrew | Director | – | Sep 10, 2026 | 1 |
| Chicko Rhonda M. | Chief Financial Officer | 25,018 | Aug 18, 2026 | 1 |
| Graul Regina Margaret | See Remarks | 107,523 | Aug 18, 2026 | 1 |
| Hecht Peter M | Director, 10% Owner | 910,240 | Jul 20, 2026 | 1 |
| Higgins Michael J | Director | 30,740 | Mar 27, 2025 | 0 |
| Slate Path Capital LP | 10% Owner | 0Indirect | Nov 25, 2024 | 0 |
| Greenspan David Gerald | 10% Owner | 0Indirect | Nov 25, 2024 | 0 |
| McGuire Terrance | Director | 5,552 | Dec 4, 2023 | 0 |
| Desouza Errol B | Director | 30,000 | Dec 4, 2023 | 0 |
| Hyman Steven | Director | 20,000 | Dec 4, 2023 | 0 |
| Conrades George H | Director | – | Jun 16, 2022 | 0 |
| Fanucci Marsha | Director | – | Jun 16, 2022 | 0 |
| Mendelsohn Michael | Director | – | Jun 16, 2022 | 0 |
| Isacson Ole | Director | – | Jun 16, 2022 | 0 |
| Lovell Stephanie | Director | – | Jun 16, 2022 | 0 |
| Busch Andreas | Chief Scientific Officer | – | Jan 24, 2022 | 0 |
| Gault Cheryl | Chief Operating Officer | – | Jan 24, 2022 | 0 |
| Gjino Anjeza | Chief Financial Officer | – | Jan 24, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 (view filing)4:05 PM ET | Nov 21 | 4 days | Slate Path Capital LP and 1 other10% Owner | SSaleCommon Stock, no par value | −357.9K | $1.55 | −$555.1K | −100.0%0 after | |
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | McGuire TerranceDirector | SSale | −8 | $3.40 | −$27.2 | −100.0%0 after |